Navigation Links
ASCO Results: Oncologists Rank Genentech Number One

SAN MATEO, Calif., June 10 /PRNewswire/ -- When asked which company stood out at last week's ASCO conference in Chicago, oncologists cited Genentech at the top of the list, according to AlphaDetail, Inc., a leader in oncology primary market research and influence network mapping solutions to the Global Life Sciences Industry.

In a brief on-line survey of 103 oncologists conducted soon after the close of the conference, AlphaDetail was able to gather some interesting feedback about oncologist perceptions of the meeting. The ASCO Annual Meeting attracts more than 30,000 attendees and is considered the premier educational and scientific event in the oncology community.

-- 60% of US oncologists attended the ASCO Annual Meeting.

-- Oncologists rate Genentech #1 on overall image in oncology and cite it

as the top company that stood out above the others at ASCO.

-- Oncologists cite the following as the three most important pieces of

data presented at ASCO:

-- KRAS status predicts response to first-line cetuximab for

metastatic colorectal cancer.

-- Erbitux (cetuximab) + platinum-based chemotherapy extends overall

survival in NSCLC vs. chemotherapy alone.

-- Zometa (zoledronic acid) increases survival for premenopausal

patients who received adjuvant endocrine therapy for early breast


To learn more about this study, please contact Bob Latshaw at or (215) 259-5601.

About AlphaDetail, Inc.:

At AlphaDetail, we have an unparalleled commitment to our clients. We are a full-service primary market research firm, with a particular emphasis in large and complex quantitative studies for the global healthcare community. AlphaDetail is built on one of the industry's strongest foundations that includes a large team of exceptional analytical specialists, the industry's leading technology platform and a flexible approach to research that helps us to answer our client's most challenging questions.

SOURCE AlphaDetail, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales
2. Oncologists Want to See Significant Improvement in Overall Survival Before Adopting Targeted Polytherapy in a First-Line Setting
3. Thomas W. Burke, MD, Elected 40th President of the Society of Gynecologic Oncologists
4. Amgen and Genentech Brace Themselves for Heavy Pressure From Biogenerics Manufacturers
5. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
6. Sangamo BioSciences Announces Expansion of Research and License Agreement With Genentech for ZFP Technology for Protein Pharmaceutical Production
7. BioWa Announces Expansion of License Agreement with Genentech for BioWas POTELLIGENT(R) Technology
8. Option to Develop Exelixis Compound Exercised By Genentech
9. AUDIO from Medialink and Pfizer: Hispanic Heritage Month Reminds Us Increasing Numbers of Hispanic-Americans Do Not Have Health Insurance
10. The neural basis of number sense in young infants
11. BioSpace Career Fair in San Diego Draws Record Number of Bioscience Candidates
Post Your Comments:
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. , ... tests introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... today announced the launch of the Supplyframe Design Lab . Located in ... to explore the future of how hardware projects are designed, built and brought ...
(Date:6/23/2016)...  Blueprint Bio, a company dedicated to identifying, protecting ... has closed its Series A funding round, according to ... "We have received a commitment from Forentis Fund that ... meet our current goals," stated Matthew Nunez . ... complete validation on the current projects in our pipeline, ...
Breaking Biology Technology:
(Date:5/12/2016)... 2016 , a brand of ... results from the Q1 wave of its quarterly wearables ... consumers, receptivity to a program where they would receive ... insurance company. "We were surprised to see ... Michael LaColla , CEO of Troubadour Research, "primarily because ...
(Date:4/26/2016)... LONDON , April 26, 2016 ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... a partnership to integrate the Onegini mobile security ... (Logo: ) The ... enhanced security to access and transact across channels. ...
(Date:4/14/2016)... 2016 BioCatch ™, the ... announced the appointment of Eyal Goldwerger as ... Goldwerger,s leadership appointment comes at a time of ... deployment of its platform at several of the world,s ... discerns unique cognitive and physiological factors, is a winner ...
Breaking Biology News(10 mins):